Shuang xiao Jiang

Dr. Shuang xiao Jiang

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 March 2023 in Frontiers in Ophthalmology
Verified
Journal Article
Open access
FLFanfei Liu
Fanfei Liu
MWMinjin Wang
Minjin Wang
MLMeng Liao
Meng Liao
LLLongqian Liu
Longqian Liu
SJShuang xiao Jiang
Shuang xiao Jiang
Background: Idiopathic congenital nystagmus (ICN) is an inherited disorder characterized by uncontrollable binocular conjugating oscillation. X-linked idiopathic congenital nystagmus is one of the most prevalent types of ICN. Elucidation of the genetic mechanisms involved in ICN will enhance our understanding of its molecular etiology.Case presentation: We report a girl with uncontrollable binocular oscillation and anomalous head posture, then presented a novel heterozygous missense variant (c.686G>T) within the mutation-rich region of the FERM domain containing 7 (FRMD7) gene in her family member. The girl received occlusion therapy and surgical operation which balanced her binocular vision and corrected the anomalous head posture.Conclusions: This is the first report on a mutation (c.686G>T) caused the substitution of Arg (R) with Leu (L) at position 229 (p.R229L) of the FRMD7 protein in a patient with ICN.

30 September 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
GLGuina Liu
Guina Liu
GSGuojiao Song
Guojiao Song
Siqi WangSiqi Wang
Siqi Wang
WXWei Xu
Wei Xu
HZHanqing Zhao
Hanqing Zhao
HLHongtao Liu
Hongtao Liu
Objectives: To estimate the incidence of reported retinal detachment (RD) after primary anti-vascular endothelial growth factor (anti-VEGF) treatment for retinopathy of prematurity (ROP) and to explore study-level factors associated with RD incidence. Methods: PubMed, EMBASE, Cochrane Library, and Web of Science were searched up to 24 May 2026, for English-language studies reporting RD outcomes after anti-VEGF monotherapy for ROP. Pooled incidence was estimated with a random-effects model using Freeman–Tukey double arcsine transformation. Heterogeneity, subgroup differences, publication bias, and leave-one-out sensitivity were assessed. Results: Twenty-seven studies (5598 eyes; 135 RD events) were included, comprising twelve case series, thirteen cohort studies, and two randomized controlled trials; thus, the evidence was predominantly retrospective. The pooled RD incidence was 1.4% (95% CI, 0.5–2.7%; I2 = 80.8%). The estimate remained stable on leave-one-out sensitivity analysis; the exclusion of Tong et al. markedly reduced heterogeneity. Higher RD incidence was observed in Asian studies, single-center studies, and studies with predominantly Zone I ROP or aggressive ROP (AROP). Incidence varied by postmenstrual age at treatment, gestational age, birth weight, and anti-VEGF agent. No significant publication bias was detected. Conclusions: RD after primary anti-VEGF therapy for ROP is uncommon but sight-threatening, with higher incidence associated with greater disease severity and postmenstrual age. Prolonged, risk-stratified follow-up is warranted for infants with Zone I or AROP. Standardized RD definitions, subtype classification, and severity-adjusted prospective comparisons are needed.

11 June 2026 in Frontiers in Medicine
Verified
Journal Article
Open access
PDF file
JLJie Liu
Jie Liu
JZJingxin Zeng
Jingxin Zeng
PRPengfei Ren
Pengfei Ren
XKXiao Ke
Xiao Ke
FLFang Lu
Fang Lu
SJShuang xiao Jiang
Shuang xiao Jiang
Affiliation "Center for High Altitude Medicine, West China Hospital, Sichuan University" was omitted from the paper. This affiliation has now been added for authors Jie Liu and Xiaoshuang Jiang. The original version of this article has been updated.Provincial Science and Technology Department (2023NSFSC1666) and China Health Promotion Foundation (312251372). The funders played no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The original version of this article has been updated.

Verified
Journal Article
Open access
PDF file
QGQiumei Gu
Qiumei Gu
HLHongyi Liu
Hongyi Liu
Yifan XieYifan Xie
Yifan Xie
FLFang Lu
Fang Lu
ZHZiyan He
Ziyan He
SJShuang xiao Jiang
Shuang xiao Jiang
Background/Objectives: A substantial proportion of eyes with exudative macular diseases show a suboptimal response to standard-dose anti-vascular endothelial growth factor (anti-VEGF) therapy, and evidence regarding clinical outcomes after same-agent double-dose escalation remains limited. We evaluated the functional and anatomical outcomes of same-agent double-dose anti-VEGF therapy in such eyes. Methods: In this observational real-world cohort study, we retrospectively reviewed eyes with exudative macular diseases that were switched to same-agent double-dose anti-VEGF therapy because of a suboptimal response to prior standard-dose treatment. Eligibility required clinician-assessed persistent or recurrent exudative activity during the standard-dose treatment course despite at least three prior anti-VEGF injections, based on the longitudinal treatment and imaging history. Insufficient visual response and inadequate durability were considered additional, potentially overlapping features supporting dose escalation. Primary outcomes were functional and anatomical changes after switching. Secondary outcomes included injection interval, time-to-event outcomes, and associated baseline factors. Results: A total of 104 patients (111 eyes) were included. Mixed-effects modeling showed a small longitudinal improvement in BCVA of 0.007 logMAR per month (p = 0.028) and an estimated CST decrease of approximately 2.1% per month (p < 0.001). In visit-specific analyses, BCVA did not differ significantly from baseline at the first three post-switch visits and differed significantly only at the final follow-up (p = 0.004); however, the median BCVA was 0.70 logMAR at both baseline and final follow-up, and the median within-eye change was 0.00 logMAR (IQR, −0.25 to 0.10). CST was significantly lower than baseline at all post-switch visits (all p < 0.01). Among the 73 eyes with calculable paired interval data, injection intervals did not differ significantly between the standard-dose and double-dose phases (p = 0.289). Baseline pigment epithelial detachment was associated with a less favorable BCVA change (p = 0.002), and worse baseline visual acuity was associated with a higher risk of subretinal fibrosis (hazard ratio, 2.854; p = 0.002). Conclusions: In this uncontrolled pre–post cohort, anatomical changes after same-agent double-dose escalation were more consistent than functional changes. The BCVA change was statistically detectable but small in magnitude and of uncertain clinical relevance. No significant interval extension was observed among the 73 eyes with complete paired interval data during the relatively short follow-up.

11 February 2026 in PLOS ONE
Verified
Journal Article
Open access
PDF file
JZJingxin Zeng
Jingxin Zeng
WSWenwen Shang
Wenwen Shang
PRPengfei Ren
Pengfei Ren
XKXiao Ke
Xiao Ke
YZYonghao Zhao
Yonghao Zhao
SJShuang xiao Jiang
Shuang xiao Jiang
Objective: Neovascular age-related macular degeneration (nAMD) is characterized by pathological neovascularization in the macula, leading to irreversible central vision loss. This study aimed to evaluate cytokine profiles in the aqueous humor of nAMD patients and explore correlation between specific cytokines, clinical characteristics, and retinal morphological features. Methods: Our protocol was registered on Chinese Clinical Trial Registry (ChiCTR) under registration number ChiCTR2500106190 and approved by the Biomedical Research Ethics Committee of West China Hospital, Sichuan University (ID: 20231375). A total of 94 patients with nAMD and 34 cataract patients as the control group were enrolled. Aqueous humor samples were collected before anti-VEGF treatment or cataract surgery, and analyzed using cytometric bead array (CBA) for cytokines (MCP-1, ICAM-1, VCAM-1, CA-1, β-FGF, PPK/PK, and VEGF). Retinal structural biomarkers were assessed using optical coherence tomography (OCT), with statistical analysis performed to evaluate correlations between cytokine levels and retinal morphology. Results: Compared to cataract patients, nAMD patients exhibited elevated levels of CA-1, PPK/PK, ICAM-1, VCAM-1, and MCP-1 (P < 0.05). Baseline best-corrected visual acuity (BCVA) was reduced in nAMD patients with intraretinal fluid (IRF) or pigmentation compared to those without (P < 0.05). Visit BCVA also deteriorated in patients with fibrosis (P < 0.05). Additionally, central foveal thickness (CTR) was significantly thinner in patients with PED or SRF (P < 0.05). Visit BCVA demonstrated positive correlations with baseline BCVA (r = 0.689, P < 0.001). In contrast, the presence of fibrosis and elevated MCP-1 concentration was associated with a poorer visual outcome. In correlation analysis, β-FGF exhibited a negative correlation with CA-1, PPK, ICAM-1. VCAM-1 and MCP-1. Conclusion: In this cross-sectional study, the presence of IRF was significantly associated with reduced BCVA in nAMD patients. Baseline BCVA emerged as a critical predictor of visual prognosis in nAMD. Notably, retinal fibrosis development and elevated MCP-1 level linked to worse clinical outcomes, underscoring their potential as therapeutic targets. While recent anti-VEGF injections decreased VEGF levels in aqueous humor of nAMD patients, the impact of these agents on other cytokines remain unclear, suggesting a need for adjunct therapies to address multifaceted pathogenic pathways.

2 April 2026 in Frontiers in Medicine
Verified
Journal Article
Open access
PDF file
JLJie Liu
Jie Liu
JZJingxin Zeng
Jingxin Zeng
PRPengfei Ren
Pengfei Ren
XKXiao Ke
Xiao Ke
FLFang Lu
Fang Lu
SJShuang xiao Jiang
Shuang xiao Jiang
Purpose: This study aimed to investigate the expression of carbonic anhydrase-1 (CA-1) in the aqueous humor of patients with diabetic macular edema (DME) and to explore its correlations with other cytokines and macular structure in a real-world setting. Methods: This was a retrospective cross-sectional study. A total of 74 patients were enrolled in the DME group, and 30 patients were included in the control group. Aqueous samples were collected before intravitreal injections or relevant surgical procedures. The concentrations of CA-1, prekallikrein (PK), intercellular adhesion molecule-1 (ICAM-1), vascular intercellular adhesion molecule-1 (VCAM-1), monocyte chemoattractant protein-1 (MCP-1), vascular endothelial growth factor (VEGF), interleukin-6 (IL-6), and interleukin-8 (IL-8) were measured using a cytometric bead array (CBA). Retinal structural biomarkers were examined using optical coherence tomography (OCT) and fundus photography. Results: The levels of CA-1 in the aqueous humor were markedly elevated in patients with DME compared to the control group. The DME group showed a significantly higher geometric mean CA-1 level than the control group (geometric mean ratio = 10.65, 95% CI: 3.64–31.14, p < 0.001). Receiver-operating characteristic curve analyses (AUC = 0.89; 95% CI: 0.871–0.981, p < 0.001) revealed that CA-1 has a strong discriminatory ability for distinguishing DME patients. In addition, other cytokines (PK, ICAM-1, VCAM-1, and IL-8) in the aqueous humor were elevated in the DME group compared to the control group ( p < 0.05). In the DME group, CA-1 levels exhibited positive correlations with PK, ICAM-1, VCAM-1, MCP-1, VEGF, IL-6, and IL-8 ( r = 0.306, 0.551, 0.347, 0.589, 0.349, 0.248, and 0.538, respectively; all p < 0.05). Conversely, CA-1 levels showed a negative correlation with retinal hemorrhage ( r = −0.330, p = 0.016) and did not show significant association with other macular structural parameters. Conclusion: In DME patients, CA-1 levels were significantly elevated and showed associations with PK, ICAM-1, VCAM-1, VEGF, MCP-1, IL-6, and IL-8. These findings suggest that higher CA-1 levels are associated with increased retinal vascular permeability and inflammation in patients with DME. Clinical trial registration: https://www.chictr.org.cn/index.html , identifier 268319.